Clinical Trial Update: Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients [Phase 3]

View source ↗

Summary

Phase 3 study comparing dose escalation versus no dose escalation of imatinib in metastatic gastrointestinal stromal tumors was terminated; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: TERMINATED | Results posted: 2013-08-16